Finally, promoting angiogenesis by endothelial specific disruption of Protein Tyrosine Phosphatase Non-Receptor Type 1 (Ptpn1) (Gogiraju et al., 2016), Tumor Protein P53 (Tp53) (Gogiraju et al., 2015) or Lepr (Gogiraju et al., 2019) was shown to improve TAC-induced cardiac hypertrophy and systolic dysfunction. Here, TP53 is linked to cardiac hypertrophy.